350 rub
Journal Technologies of Living Systems №3 for 2016 г.
Article in number:
Metabolic syndrome and the risk of neurodegenerative diseases
Keywords: Alzheimer's disease Parkinson's disease multiple sclerosis indices of Metabolic syndrome blood cholesterol correlation and regression analysis
Authors:
L.A. Radkevich - Dr. Sc. (Biol.), Professor, Deputy Director of Sciences, Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences, Moscow. E-mail: rlactp@gmail.com A.S. Kabankin - Dr. Sc. (Biol.), Chief Research Scientist, Center for Theoretical Problems of Physico-Chemical Pharma-cology of the Russian Academy of Sciences, Moscow. E-mail: kabankin_a@mail.ru A.V. Sintsov - Ph.D., (Biol.), Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences, Moscow. E-mail: sintsov@insysbio.ru D.A. Radkevich - Student. E-mail: rlactp@gmail.com
Abstract:
By means of Spearman-s nonparametric correlation analysis an association of indicators of a metabolic syndrome (МS) in 170 countries with incidence rates of Alzheimer-s desease (AD), Parkinson-s desease (PD) and a multiple sclerosis (MuSc) in them is investigated. Significant positive correlation of some indicators of МS with incidence rates of AD, PD and MuSc is established. and for MuSc correlation coefficients with all indicators of MS are more than for AD and PD. The closest as-sociation of incidence rates of AD, PD andMuSc is noted with such indicators of MS as a share of the population with cho-lesterol in blood ≥ 5.0 mmol⁄l and a share of the population with an index of weight of a body ≥ 25 kg⁄м2. By means of multiple regression analysis the equations quantitatively connecting incidence rates of AD, PD and MuSc with shares of the population with cholesterol in blood ≥ 5.0 ммол⁄л are received. From the equations it follows that reduction in 2 times of an average indice of the countries - % of people with a level холестерина ≥5.0 mmol/l can lower average incidence rates of AD on 88,7 %, PD - on 82,2 % and MuSc - on 42,7 %.
Pages: 38-45
References

 

  1. Babizhayev M.A.,Kasus-Jacobi A.,Vishnyakova K.S.,Yegorov Y.E.Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision. Recent Pat Endocr Metab Immune Drug Discov. 2014. Jun 8. [Epub ahead of print].
  2. Franke K.,Ristow M.,Gaser C.Alzheimer\'s Disease Neuroimaging Initiative. Gender-specific impact of personal health parameters on individual brain aging in cognitively unimpaired elderly subjects // Front Aging Neurosci. 2014 May. V.23. № 6. R. 94. doi: 10.3389/fnagi.2014.00094. eCollection 2014.
  3. Larouche E.,Hudon C.,Goulet S. Potential benefits of mindfulness-based interventions in mild cognitive impairment andAlzheimer\'s disease // An interdisciplinary perspective. Behav Brain Res. 2014. Jun 2. pii: S0166-4328(14)00361-1. doi: 10.1016/j.bbr.2014.05.058. [Epub ahead of print].
  4. Lee E.B.,Mattson M.P. The neuropathology of obesity: insights from human disease // Acta Neuropathol. 2014 Jan. V.127. № 1. R. 3-28. doi: 10.1007/s00401-013-1190-x. Epub 2013 Oct 6.
  5. Ryo M.,Furiya Y.,Ueno S. Metabolic syndrome //Nihon Rinsho.2014 Apr. V.72. № 4. R. 702-707.
  6. Whayne T.F. (Jr.)Ischemic heart disease and the Mediterranean diet // Curr. Cardiol. Rep. 2014 Jun. V.16. № 6. R. 491. doi: 10.1007/s11886-014-0491-6.
  7. Luque-Contreras D.,Carvajal K.,Toral-Rios D.,Franco-Bocanegra D.,Campos-Peña V. Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer\'s disease? // Oxid. Med. Cell. Longev. 2014.  R. 2014:497802. doi: 10.1155/2014/497802. Epub 2014 Jan 20.
  8. Segatto M.,Leboffe L.,Trapani L.,Pallottini V. Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline // Curr Med Chem. 2014. Mar 3. [Epub ahead of print].
  9. World Health Organization. http://apps.Who.int/gho/ indicatorregistry/App_Main/view_indicator.aspx-iid= 2379; 2381; 2382; 2383; 2385; 2386; 2389; 2390.
  10. World Health Organization. The global burden of disease: 2004 update. Geneva, WHO, 2008. Available at www. who.int/evidence/bodbodgbddeathdalyestimates.xls.
  11. Lu B., Gehrke S.,Wu Z. RNA metabolism in the pathogenesis of Parkinsons disease // Brain Res.2014 Mar 13. pii: S0006-8993(14)00329-1. doi: 10.1016/j.brainres.2014.03.003.
  12. Filippi M., Bozzati M., Rovaris M., et al. Evidence for widespread axonal dam age at the earliest clinical stage of multiple sclerosis // Brain. 2003. V. 1. № 26(Pt. 2). R. 433-437.
  13. Reed B.,Villeneuve S.,Mack W.,DeCarli C.,Chui HC.,Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis // JAMA Neurol. 2014 Feb. V. 71. № 2. R. 195-200. doi:10.1001/jamaneurol.2013.5390.
  14. Rizvi S.A., Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis // Neurology. 2004. № 63. R. S47-S54.
  15. Malfitano A.M.,Marasco G.,Proto M.C.,Laezza C.,Gazzerro P.,Bifulco M. Statins in neurological disorders: An overview and update // Pharmacol Res. 2014. Jun. 19. pii: S1043-6618(14)00099-1. doi: 10.1016/ j.phrs.2014.06.007.